Insertions in the Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Genes: Clinical Impact and Molecular Mechanisms

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2005 Jun 28

PMID 15980322

Citations 15

Authors

Mark A Winters

Thomas C Merigan

Affiliations

Soon will be listed here.

Citing Articles

HIV Protease Hinge Region Insertions at Codon 38 Affect Enzyme Kinetics, Conformational Stability and Dynamics.

Sheik Ismail Z, Worth R, Mosebi S, Sayed Y Protein J. 2023; 42(5):490-501.

PMID: 37421557 PMC: 10480237. DOI: 10.1007/s10930-023-10132-6.

Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.

Marin R, Behl T, Negrut N, Bungau S Biomedicines. 2021; 9(3).

PMID: 33803812 PMC: 8003312. DOI: 10.3390/biomedicines9030313.

Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses.

Pham H, Hassounah S, Keele B, Van Rompay K, Mesplede T Clin Infect Dis. 2019; 69(8):1460-1461.

PMID: 30753366 PMC: 7320072. DOI: 10.1093/cid/ciz136.

GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.

Grantz Saskova K, Kozisek M, Stray K, De Jong D, Rezaova P, Brynda J J Virol. 2013; 88(6):3586-90.

PMID: 24371077 PMC: 3957959. DOI: 10.1128/JVI.02688-13.

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Li Z, Terry B, Olds W, Protack T, Deminie C, Minassian B Antimicrob Agents Chemother. 2013; 57(11):5500-8.

PMID: 23979732 PMC: 3811251. DOI: 10.1128/AAC.01195-13.

References

Haubrich R, Kemper C, Hellmann N, Keiser P, Witt M, Forthal D . The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002; 16(15):F33-40. DOI: 10.1097/00002030-200210180-00001. View

Whitcomb J, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G . Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS. 2002; 16(15):F41-7. DOI: 10.1097/00002030-200210180-00002. View

Rhee S, Gonzales M, Kantor R, Betts B, Ravela J, Shafer R . Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003; 31(1):298-303. PMC: 165547. DOI: 10.1093/nar/gkg100. View

Meyer P, Lennerstrand J, Matsuura S, Larder B, Scott W . Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J Virol. 2003; 77(6):3871-7. PMC: 149510. DOI: 10.1128/jvi.77.6.3871-3877.2003. View

Ibe S, Shibata N, Utsumi M, Kaneda T . Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy. Microbiol Immunol. 2003; 47(1):71-9. DOI: 10.1111/j.1348-0421.2003.tb02788.x. View

Selmi B, Deval J, Boretto J, Canard B . Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues. Antivir Ther. 2003; 8(2):143-54. View

Moreno S, Casado J, Perez-Elias M, Dronda F, Antela A, Moreno A . Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1. AIDS. 2003; 17(9):1413-4. DOI: 10.1097/00002030-200306130-00026. View

Hirsch M, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes D, DAquila R . Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003; 37(1):113-28. DOI: 10.1086/375597. View

Fikkert V, Van Maele B, Vercammen J, Hantson A, Van Remoortel B, Michiels M . Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol. 2003; 77(21):11459-70. PMC: 229256. DOI: 10.1128/jvi.77.21.11459-11470.2003. View

10.

Sturmer M, Staszewski S, Doerr H, Hertogs K . A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure. AIDS Res Hum Retroviruses. 2003; 19(11):967-8. DOI: 10.1089/088922203322588314. View

11.

Rambaut A, Posada D, Crandall K, Holmes E . The causes and consequences of HIV evolution. Nat Rev Genet. 2004; 5(1):52-61. DOI: 10.1038/nrg1246. View

12.

Myint L, Matsuda M, Matsuda Z, Yokomaku Y, Chiba T, Okano A . Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004; 48(2):444-52. PMC: 321554. DOI: 10.1128/AAC.48.2.444-452.2004. View

13.

Schneider V, LeGoff J, Belec L, Delphin N, Dutreuil C, Kara-Mostefa A . Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure. Clin Microbiol Infect. 2004; 10(2):127-36. DOI: 10.1111/j.1198-743x.2003.00864.x. View

14.

White K, Chen J, Margot N, Wrin T, Petropoulos C, Naeger L . Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother. 2004; 48(3):992-1003. PMC: 353090. DOI: 10.1128/AAC.48.3.992-1003.2004. View

15.

Kagan R, Winters M, Merigan T, Heseltine P . HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. AIDS Res Hum Retroviruses. 2004; 20(1):1-9. DOI: 10.1089/088922204322749440. View

16.

Lee D, Robinson Jr W . Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid. J Virol. 2004; 78(11):5835-47. PMC: 415810. DOI: 10.1128/JVI.78.11.5835-5847.2004. View

17.

Matamoros T, Franco S, Vazquez-Alvarez B, Mas A, Martinez M, Menendez-Arias L . Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked.... J Biol Chem. 2004; 279(23):24569-77. DOI: 10.1074/jbc.M312658200. View

18.

Goldschmidt V, Marquet R . Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004; 36(9):1687-705. DOI: 10.1016/j.biocel.2004.02.028. View

19.

G Prado J, Franco S, Matamoros T, Ruiz L, Clotet B, Menendez-Arias L . Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology. 2004; 326(1):103-12. DOI: 10.1016/j.virol.2004.06.006. View

20.

Greenberg M, Cammack N . Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004; 54(2):333-40. DOI: 10.1093/jac/dkh330. View